Management of Dejerine-Roussy Syndrome in a 73-Year-Old Female
This patient requires immediate neurology referral for confirmation of diagnosis and initiation of pharmacological therapy with either a secondary-amine tricyclic antidepressant (nortriptyline or desipramine) or a calcium channel α2-δ ligand (gabapentin or pregabalin) as first-line treatment for this central post-stroke neuropathic pain syndrome 1, 2.
Understanding the Condition
Dejerine-Roussy syndrome is central post-stroke pain (CPSP) that typically presents 3-6 months after a cerebrovascular accident, manifesting as painful paresthesias contralateral to the thalamic lesion 2. The right-sided shoulder-to-foot pain pattern this patient describes is classic for a left thalamic stroke affecting the ventral posterior nuclei.
Immediate Actions
Neurology Referral
- Essential for diagnostic confirmation through clinical examination and imaging (CT or MRI to visualize the infarcted thalamic area) 2
- The neurologist will assess for sensory abnormalities, allodynia, and hyperalgesia that characterize this syndrome 3
- Rule out other causes and confirm the diagnosis before committing to long-term treatment
Pharmacological Management Algorithm
Step 1: First-Line Therapy (Choose One)
Option A - Secondary-Amine TCA:
- Nortriptyline or desipramine (preferred over amitriptyline in elderly) 1
- Critical caveat for 73-year-old: Obtain screening ECG before starting, limit dose to <100 mg/day, use with extreme caution if cardiac disease present 1
- Allow 6-8 weeks for adequate trial, including 2 weeks at highest tolerated dose 1
Option B - Calcium Channel α2-δ Ligand:
- Gabapentin or pregabalin 1
- Safer cardiac profile for elderly patients
- Requires 2-4 weeks titration to efficacious dose
Option C - SSNRI:
- Duloxetine 60 mg daily (start 30 mg × 1 week to reduce nausea) 1
- Venlafaxine 150-225 mg/day (requires 2-4 weeks titration) 1
Step 2: Assess Response After Adequate Trial
- Target: Pain ≤3/10 with tolerable side effects 1
- If partial relief (pain ≥4/10): Add a second first-line medication from different class 1
- If <30% pain reduction: Switch to alternative first-line medication 1
Step 3: Refractory Cases
If first-line monotherapy and combination therapy fail 1:
- Refer to pain specialist or multidisciplinary pain center
- Consider advanced interventions: deep brain stimulation (ventral posterior medial/lateral thalamic nuclei targets show efficacy) 4
- Novel option: Scrambler therapy (neuromodulation via external electrodes) showed dramatic response in case reports 5
Additional Considerations for This 73-Year-Old
Topical Therapy Adjunct
- Topical lidocaine can be added for localized neuropathic pain areas (shoulder or foot) 6
- Strong recommendation for elderly with neuropathic pain, minimal systemic effects 6
Opioid Caution
- Reserve for acute exacerbations or breakthrough pain during medication titration 1
- CPSP is notoriously refractory to opioids with only modest pain reduction 2
- If used, anticipate and manage constipation aggressively in elderly 6
Critical Pitfalls to Avoid
- Cardiac toxicity in elderly: TCAs require ECG screening and dose limitation in patients >40 years 1
- Premature treatment abandonment: Allow full 6-8 week trials before declaring failure 1
- Monotherapy persistence: If partial response, add second agent rather than abandoning effective partial treatment 1
- Expecting complete resolution: CPSP often requires combination therapy and realistic expectations of 50% pain reduction as success 4
Why This Approach
The guideline-based stepwise algorithm 1 provides the strongest framework, with neuropathic pain management principles directly applicable to CPSP 2. The 2020 comprehensive review confirms pharmacologic management remains first-line despite frequent treatment resistance 2, making systematic trials of multiple agents essential before considering invasive procedures.